Swissmedic Updates
The latest guidances, approvals, and safety alerts from Swissmedic, curated by automated regulatory intelligence.
Extends the deadline for publishing officially mandated information materials on the Swiss electronic publication platform, reducing near-term compliance…
Brings additional psychoactive “designer drugs” under Swiss control, expanding regulatory coverage to new substances with potential public-health and abuse…
Highlights that misuse or illegal marketing of NAD+ “lifestyle” supplements may trigger criminal consequences, signaling a stricter enforcement posture against…
Provides implementation guidance for publishing and submitting regulatory dossiers using the eCTD v4.0 standard, aiming to standardize how companies format and…
Announces a Swissmedic Clinical Trials Symposium 2027, likely serving as an informational forum for updates and discussion of current clinical trial…
Introduces the requirement to submit notifications of major changes through the Swissmedic Portal starting 1 November 2026.
Clarifies additional information to support the Swiss parallel import pathway under TPA Art.
Modification of the “Form DMF” indicates updates to the Drug Master File submission/administrative documentation framework that sponsors and DMF holders must…
Updates the Swiss regulatory forms used for submitting new applications for human medicinal products and for submitting variations/extensions to authorization…
Introduces a new regulatory strategy aimed at reducing reliance on animal testing during medicinal product development while still preserving scientifically…
Clarifies expectations for GMP compliance for manufacturing conducted by foreign manufacturers, indicating that Swiss requirements may be applied through…
Clarifies or updates Swiss guidance on the conditions and documentation expectations for importing human medicinal products under Art. 14 para.
Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances, indicating that regulatory expectations…
Revision of the Swissmedic guidance for authorisation of biosimilars may refine the regulatory expectations for demonstrating biosimilarity, including how…
Swissmedic Portal updates will introduce new online functionality available from 23 September 2026, requiring regulated entities to prepare for changes in how…
Defines or clarifies Swiss regulatory expectations for notifications submitted under Article 41 of the MPLO framework.
ElViS 2.0 appears to be a Swiss regulatory update focused on a system/process commonly used for regulatory interactions, but the provided document content does…
Webinar content likely provides an update on Swissmedic regulatory expectations, but the provided document text contains no substantive policy or procedural…
Simplifies Swissmedic application procedures for changing a veterinary medicinal product’s status between its main authorisation and an export licence.
FAQ on Swissmedic Fees Ordinance provides interpretive clarification on how Swissmedic fees are assessed and managed under the Fees Ordinance.